emavusertib Search Results


irak4 inhibitor ca 4948  (MedChemExpress)
94
MedChemExpress irak4 inhibitor ca 4948
Irak4 Inhibitor Ca 4948, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/irak4 inhibitor ca 4948/product/MedChemExpress
Average 94 stars, based on 1 article reviews
irak4 inhibitor ca 4948 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
emavusertib (irak4i)  (Curis Inc)
90
Curis Inc emavusertib (irak4i)
( A ) List of studies, registered at ‘clinical trials.gov’, including new target drugs, currently recruiting FLT3mut AML. ( B ) List of studies, registered at clinical trials.gov, including immunotherapy, currently recruiting FLT3mut AML patients.
Emavusertib (Irak4i), supplied by Curis Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/emavusertib (irak4i)/product/Curis Inc
Average 90 stars, based on 1 article reviews
emavusertib (irak4i) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


( A ) List of studies, registered at ‘clinical trials.gov’, including new target drugs, currently recruiting FLT3mut AML. ( B ) List of studies, registered at clinical trials.gov, including immunotherapy, currently recruiting FLT3mut AML patients.

Journal: Cancers

Article Title: FLT3-Mutated Leukemic Stem Cells: Mechanisms of Resistance and New Therapeutic Targets

doi: 10.3390/cancers16101819

Figure Lengend Snippet: ( A ) List of studies, registered at ‘clinical trials.gov’, including new target drugs, currently recruiting FLT3mut AML. ( B ) List of studies, registered at clinical trials.gov, including immunotherapy, currently recruiting FLT3mut AML patients.

Article Snippet: I , NCT04278768 , RR , Emavusertib (IRAK4i)/Ven https://clinicaltrials.gov/study/NCT04278768?cond=NCT04278768&rank=1 , accessed on 17 March 2024 , Curis, Inc..

Techniques: